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Abstract
Esophageal complications caused by gastroesophageal 
reflux disease (GERD) include reflux esophagitis and 
Barrett’s esophagus (BE). BE is a premalignant condition 
with an increased risk of developing esophageal adeno­
carcinoma (EAC). The carcinogenic sequence may 
progress through several steps, from normal esophageal 
mucosa through BE to EAC. A recent advent of functional 
esophageal testing (particularly multichannel intraluminal 
impedance and pH monitoring) has helped to improve 
our knowledge about GERD pathophysiology, including its 
complications. Those findings (when properly confirmed) 
might help to predict BE neoplastic progression. Over the 
last few decades, the incidence of EAC has continued to 
rise in Western populations. However, only a minority of 
BE patients develop EAC, opening the debate regarding 
the cost­effectiveness of current screening/surveillance 
strategies. Thus, major efforts in clinical and research 
practice are focused on new methods for optimal risk 
assessment that can stratify BE patients at low or high 
risk of developing EAC, which should improve the cost 
effectiveness of screening/surveillance programs and 
consequently significantly affect health­care costs. 
Furthermore, the area of BE therapeutic management is 
rapidly evolving. Endoscopic eradication therapies have 
been shown to be effective, and new therapeutic options 
for BE and EAC have emerged. The aim of the present 
review article is to highlight the status of screening/
surveillance programs and the current progress of BE 
therapy. Moreover, we discuss the recent introduction of 
novel esophageal pathophysiological exams that have 
improved the knowledge of the mechanisms linking 
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Core tip: The review highlights the significant progress 
in the diagnostic and therapeutic management of 
Barrett’s esophagus (BE) thanks to the development 
of up­and­coming endoscopic technologies. Moreover, 
we discuss the recent introduction of novel esophageal 
pathophysiological exams that have improved the 
knowledge of the mechanisms implicated in the genesis 
of esophageal mucosal damage, paving the way to the 
future possibility of predicting BE neoplastic progression. 
The comparison of endoscopic surveillance and 
eradication therapy recommendations for BE in currently 
available guidelines are provided.
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INTRODUCTION
Gastroesophageal reflux disease (GERD) is defined as 
a condition that develops when the reflux of stomach 
contents causes troublesome symptoms and/or com­
plications[1]. Esophageal complications caused by GERD 
include reflux esophagitis and Barrett’s esophagus 
(BE), and the latter predisposes patients to esophageal 
adenocarcinoma (EAC)[1]. BE is a premalignant condition 
in which the normal stratified squamous epithelium of 
the distal esophagus is replaced by columnar mucosa 
with intestinal specialized metaplasia[2]. 
GERD is a worldwide disease, and evidence suggests 
an overall increase in its prevalence since 1995[3,4]. As 
a result, costs related to GERD diagnosis, treatment 
and surveillance represent a substantial commitment 
of economic resources[5]. In parallel, over the last few 
decades, the incidence of EAC has continued to rise 
in Western populations[6­8]. The totality of evidence 
supports the idea that the different racial, ethnic and 
gender distributions of BE may drive the risk of EAC, 
with incidence rates much higher among male, non­
Hispanic whites[7,9]. However, fewer than 10% of 
GERD patients are likely to progress to a diagnosis of 
BE at 5 years[10], and only a minority of BE patients 
develop EAC; the previously estimated risk of 0.5% per 
year[11­13] was recently lowered to approximately 0.3% 
per year[14,15]. Furthermore, more than 90% of EAC 
patients are not known to have BE before diagnosis[16]. 
In line with these assumptions, the current strategies 
of BE screening and surveillance programs are debated 
and show moderate to absent cost­effectiveness[17,18]. 
The aim of the present review article is to highlight 
the status of screening/surveillance programs and the 
current progress of BE therapy. Moreover, we discuss 
the recent introduction of novel esophageal pathophy­
siological exams that have improved the knowledge of 
the mechanisms linking GERD to BE. 
ESOPHAGEAL PATHOPHYSIOLOGICAL 
EXAMS
The overall characteristics and composition of the 
refluxate, together along with the dysfunction of the 
anti­reflux barrier, the impairment of mucosal defence, 
visceral motility and esophageal clearance, represent 
the complex set of mechanisms that determines GERD 
manifestation and its complications[19]. To date, it is 
well known that the refluxate may contain varying 
concentrations of acid, pepsin, or duodenal contents 
(i.e., bile acid, pancreatic enzymes) implicated in the 
development of esophageal mucosal damage[20­22]. In 
keeping with the spectrum model of GERD, several 
studies have demonstrated that severity of acid reflux 
increases from non­erosive reflux disease (NERD) 
through erosive reflux disease (ERD) up to short (i.e., 
esophageal intestinal metaplasia up to 3 cm in length, 
SSBE) and long segments (i.e., esophageal intestinal 
metaplasia more than 3 cm in length, LSBE) of BE[23­25]. 
Similarly, the presence of duodenogastroesophageal 
reflux (DGER), evaluated with a fibreoptic spectro­
photometer (Bilitec), increases significantly across the 
spectrum of GERD from NERD to BE[26­29]. Of note, 
it has been established that acid and DGER occur 
simultaneously in the majority of the reflux episodes, 
and at best, bile reflux may have a synergistic role in 
producing esophageal damage[26,27]. 
Over the past decade, the introduction of new 
technologies with which to study the esophagus from 
a functional point of view has helped improve our 
knowledge of GERD pathophysiology. The combination 
of multichannel intraluminal impedance and pH moni­
toring (MII­pH) provides a comprehensive charac­
terization of reflux episodes during a 24­h period, 
detecting both chemical (i.e., acid, weakly acidic or 
weakly alkaline) and physical properties (i.e., liquid, 
mixed, gas, proximal extension)[30]. Regarding SSBE, 
by means of monitoring only pH, the acid exposure 
time (AET) may be similar to that found in NERD and 
normal in several patients[31]. Therefore, Frazzoni et 
al[32] assessed reflux parameters via a combined MII­
pH study in newly diagnosed SSBE, at baseline and 
during proton pump inhibitor (PPI) therapy. The authors 
found that MII­pH improved the overall diagnostic yield 
because the number of reflux episodes was altered in 
more than one half of patients with normal AET off PPI. 
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Moreover, 69% of SSBE patients on PPI therapy showed 
an increased number of total reflux events, the vast 
majority of which were weakly acidic refluxes[32]. These 
findings are consistent with other studies in which the 
number of both acid and weakly acidic reflux episodes 
was increased in patients with BE[33,34]. In particular, 
Savarino et al[34] highlighted that the greater total 
exposure of esophageal mucosa to acid and weakly 
acidic reflux was due to intermittent reflux episodes. 
Indeed, the authors found a higher frequency of “re­
reflux” episodes in BE than in ERD patients[34]. “Re­
reflux” episodes (i.e., the occurrence of a further reflux 
when the basal esophageal pH is already below 4) 
represent a diagnostic advantage obtained through MII­
pH because pH­only monitoring equipment has a lower 
sampling frequency[35,36]. Moreover, intermittent reflux 
episodes determining a brief exposure of acid or bile 
might be more important than continuous exposure 
concerning the genesis of the overall alterations pro­
moting the progression of BE[37,38]. With regard to the 
role of weakly acidic refluxes, it is important to realize 
that in an environment at a pH between 4 and 5.5, 
pepsins and bile acids can still damage esophageal 
mucosa[39,40]. Given that the main consequence of PPI 
therapy is to convert acid refluxes into weakly acidic 
refluxes without significant changes in the number 
of total reflux events[41], a regression of intestinal 
metaplasia with long­term PPI therapy is somewhat 
doubtful. At last, Bredenoord et al[33] found that in 
patients with BE, only a few reflux episodes reached the 
proximal esophagus that seems to be more sensitive, 
likely explaining, at least in part, why these subjects 
often report fewer symptoms then NERD patients[42,43]. 
The recent introduction in the clinical and research 
practice of high­resolution manometry (HRM) has repre­
sented a major advance in characterizing esophageal 
motility abnormalities in GERD patients, with particular 
regard for dysfunction of the antireflux barrier and 
impaired esophageal clearance[44,45]. However, at 
present, the role of HRM in reflux remains restricted 
to preoperative testing, the identification of possible 
mechanisms and the exclusion of motility disorders[45]. 
Of note, several studies have shown that esophageal 
motility abnormalities are increasingly prevalent with 
increasing severity of GERD presentation[25,46­49]. In 
particular, Savarino et al[50] evaluated 755 GERD 
patients through conventional or impedance esophageal 
manometry and/or MII­pH testing, and they found 
that ineffective esophageal motility gradually increased 
from controls and functional heartburn to NERD and 
from ERD to BE. Likewise, the esophageal clearing 
function decreased as the severity of mucosal damage 
increased, with ERD and BE patients having the 
greatest prevalence of bolus transit abnormalities, which 
occurred also in cases of normal motility pattern[50]. 
Finally, a recent study by Frazzoni et al[51] assessed 
that neoplastic progression in SSBE was associated 
with an impairment of esophageal chemical clearance. 
Impedance can be used to measure the clearance 
of a swallowed bolus from the esophagus[52], and a 
parameter representing esophageal chemical clearance, 
named the post­reflux swallow­induced peristaltic 
wave (PSPW) index, can be obtained through MII­pH 
monitoring[53]. The impairment of chemical clearance 
represents a crucial mechanism in the pathophysiology 
of GERD and is not affected by medical or surgical 
therapy. In fact, the PSPW index has increased the 
diagnostic yield of MII­pH in GERD patients[54,55]. In this 
setting, Frazzoni et al[51] showed that the PSPW index 
was lower in SSBE patients with incident dysplasia than 
in those without it, and a PSPW index cut­off value 
of 26% was able to discriminate between these two 
groups of patients. Overall, the authors speculated that 
predicting neoplastic progression in SSBE based on a 
low PSPW index might be useful to select those patients 
deserving a close endoscopic follow­up, thus improving 
the cost­effectiveness of surveillance programs[51]. 
DIAGNOSTIC ROLE OF UPPER 
ENDOSCOPY
To date, the gold standard for the evaluation of BE 
is high­resolution white­light endoscopy with biopsy 
sampling performed according to the Seattle pro­
tocol[56­59]. The Prague classification represents a reliable 
and validated endoscopic classification of BE, which 
records the length of the esophagus involved circum­
ferentially (C) in addition to the maximal length (M) 
involved at any point[60]. 
The development of EAC in BE seems to occur 
through the progression of intestinal metaplasia to 
low­grade dysplasia (LGD) and high­grade dysplasia 
(HGD). Thus, the presence of dysplasia represents the 
most widely used marker of neoplastic progression 
in BE[61]. High­resolution endoscopes, allowing for a 
fine definition of the mucosal layer, seem to have high 
sensitivity for detecting dysplasia and BE­related early 
neoplasia[62]. Furthermore, a longer inspection time 
during white­light endoscopy seems to be associated 
with a higher detection rate of HGD/EAC[63]. 
Some studies have investigated the detection of 
intestinal metaplasia with chromoendoscopy. Available 
data regarding the improvement of methylene blue­
targeted biopsy samples, compared with random 
samples, are conflicting[64­67]. Moreover, methylene blue 
may damage DNA, so its use is not recommended[68]. 
The only randomized trial that has evaluated indigo 
carmine for the detection of dysplasia in BE has not 
found a higher rate of dysplasia than high­resolution 
white­light endoscopy[69]. Regarding virtual chro­
moendoscopy, narrow band imaging (NBI) is the most 
extensively studied in BE[70]. A meta­analysis of eight 
studies reported a NBI sensitivity and specificity of 95% 
and 65%, respectively, for the diagnosis of intestinal 
metaplasia and of 96% and 94%, respectively, for 
the diagnosis of HGD[71]. However, the interobserver 
agreement for the interpretation of NBI images is 
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and 94%. This test also appears to be more cost­
effective for screening than conventional endoscopy[95]. 
However, the Cytosponge needs further validation, 
particularly considering the lower sensitivity for SSBE 
detection.
Recently, a risk­prediction model including multiple 
demographic and clinical variables (i.e., GERD fre­
quency and duration, age, sex, race, waist­to­hip ratio, 
Helicobacter pylori status), serum levels of cytokines 
(IL12p70, IL6, IL8, IL10) and leptin obtained an area 
under the curve of 0.85, a better result than that 
achieved by other non­invasive methods[96]. 
Surveillance
Observational studies have shown that patients with 
BE receiving an EAC diagnosis during endoscopic 
surveillance have earlier­stage tumours and higher 
survival rates than those whose tumours are discovered 
because of symptoms[97,98]. However, such studies 
are susceptible to biases that could overestimate the 
benefits of surveillance. Furthermore, recent studies 
have reported a lower annual risk of progression from 
BE to EAC than previously observed (approximately 0.3% 
per year)[14,15]. The risk of progressing to EAC could also 
be lower in patients with a persistence of non­dysplastic 
BE after several surveillance endoscopies[99]. Despite 
the lack of high­quality evidence, most guidelines 
recommend surveillance endoscopy every 2­5 years 
for non­dysplastic BE, as shown in Table 1[57­59,90,100,101]. 
In cases of an indefinite diagnosis for dysplasia (IND), 
the risk of progression seems to be only in the first 
year[102], and it appears higher in patients with multifocal 
IND[103]. Current guidelines recommend a 6­12 mo 
interval to repeat, a biopsy (Table 1), and an increased 
acid suppression in cases of inflammatory infiltration 
and regenerative changes[57­59,90,100,101]. Because limited 
data are available, the natural history of LGD in BE is 
not yet clear. A recent meta­analysis found an annual 
rate of progression from LGD to EAC of 0.5% but a wide 
variability across studies[104]. The main issue for LGD 
diagnosis is a high degree of interobserver variability[105], 
in part due to the difficulty in differentiating it from 
reactive changes[106], therefore, a confirmation after 
an expert histological review is recommended[107]. 
Immunohistochemistry for p53 overexpression can be 
particularly useful to improve interobserver agreement 
for dysplasia detection[106], and it can be recommended 
as an adjunct to histopathology[58]. In patients with 
LGD on a single occasion, a repeat endoscopy in 2­12 
mo (time interval depending on the society) is recom­
mended, along with a more frequent surveillance if LGD 
is confirmed (Table 1). There is also evidence that LSBE 
patients with persistent and multifocal LGD are more 
likely to progress to EAC[108]. 
MEDICAL THERAPY
A large retrospective study highlighted how the control 
of reflux is important in the management of BE, 
moderate, and on a per­patient basis, high­resolution 
endoscopy alone seems to be sufficient to maximize 
dysplasia detection[72,73]. 
Autofluorescence imaging alone has an excessively 
high false­positive rate of dysplasia detection[74]. 
Additionally, the use of endoscopic trimodal imaging 
(i.e., high­resolution endoscopy, autofluorescence 
imaging and NBI), compared with standard endoscopy 
with random biopsy sampling, has shown contradictory 
results[75,76]. Regarding spectroscopy and optical 
coherence tomography, further studies are warranted 
to define their usefulness in BE surveillance[77,78]. 
Randomized crossover studies on the diagnostic yield 
of acetic acid­enhanced magnification endoscopy for 
BE intestinal metaplasia have produced contradictory 
data[79,80]. Using this technique, promising results 
have been obtained in dysplasia detection[81,82], and it 
also seems to be more cost­effective than the Seattle 
protocol in a high­risk population[83]. However, further 
studies are necessary to ascertain the utility of this 
technique.
Recently, the use of probe­based confocal laser 
endomicroscopy combined with high­definition white­
light endoscopy significantly improved the ability to 
detect neoplasia in BE patients compared with high­
definition white­light endoscopy[84,85]. 
Finally, molecular imaging, exploiting fluorescently 
labelled molecules that bind with a different affinity 
to dysplastic and non­dysplastic cells, is a promising 
technique[86,87]. In a recent study, using a novel peptide 
that binds to areas of HGD and neoplasia, Sturm et 
al[88] reported 75% sensitivity and 97% specificity for 
neoplasia. 
Screening
Because the proportion of EAC patients with a prior 
diagnosis of BE is low, and given the low incidence of 
EAC in BE[15,89], performing a screening program for BE 
with endoscopy in an unselected population is not cost­
effective. Currently, most medical societies suggest 
endoscopic screening for BE in patients with chronic 
GERD symptoms and multiple risk factors (i.e., 50 
years of age or older, white race, male gender, obesity, 
history of smoking, family history for BE or EAC)[58,59] or 
in men older than 60 years with reflux symptoms for 10 
years[90]. 
New methods for BE screening are being evaluated 
with some promising results. Transnasal endoscopy 
is a well­tolerated method, and it seems to have 
good accuracy, but further validation is necessary[91]. 
Moreover, biopsy specimens taken with these endos­
copes are small, which could increase sampling bias and 
hinder the interpretation[92]. 
Cytosponge is a non­endoscopic esophageal sam­
pling device coupled with immunocytochemistry for 
trefoil factor 3, a marker of columnar epithelium with 
intestinal metaplasia[93,94]. In a study involving 504 
patients, Kadri et al[93] reported a sensitivity and a 
specificity for the detection of BE of, respectively, 73% 
Martinucci I et al . Barrett’s esophagus
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drugs[116]. To ascertain the efficacy of chemoprevention 
with PPIs and/or aspirin in BE metaplasia, a large clinical 
trial (Aspirin Esomeprazole Chemoprevention Trial ­ 
AspECT) was planned, the results of which are expected 
in 2016[117]. 
Although the exact dose of PPIs and the therapeutic 
efficacy endpoint are not known, high­dosage PPIs 
are commonly prescribed in clinical practice. However, 
the currently available international guidelines are 
not in a total agreement regarding recommendations 
for the maintenance treatment with PPIs in patients 
with BE. The recent international Benign Barrett’s and 
Cancer Taskforce (BOB CAT) consensus group hints 
at using medical over surgical therapies to prevent 
BE neoplastic progression[90]. The Australian Clinical 
Practice Guidelines suggests that only symptomatic 
patients with BE should be treated with PPI therapy, 
with the dose titrated to control symptoms[57]. According 
to the British Society of Gastroenterology, there is not 
yet sufficient evidence to recommend acid­suppression 
drugs as chemopreventive agents, even if PPIs have 
the best clinical profile for symptom management[58]. 
Moreover, the American Gastroenterological Association 
(AGA) highlighted that PPI therapy also has effects 
that, conceivably, might promote the development 
of cancer in BE (i.e., increasing the serum levels of 
gastrin, a hormone than can induce proliferation in 
BE epithelium)[59]. Because the evidence to support 
potent acid suppression with PPIs as a chemopreventive 
strategy in BE is largely indirect, the AGA asserts 
that insufficient data are available to advocate the 
prescription of PPIs in dosages higher than those 
necessary to eliminate the symptoms and endoscopic 
signs of GERD or, for patients without such symptoms 
and signs, in dosages higher than those suggested as 
conventional for GERD treatment. Likewise, there are 
not sufficient data to support the use of esophageal pH 
monitoring to titrate the PPI dosage to normalize AET in 
patients with BE[59]. 
ENDOSCOPIC THERAPY
Over the past decade, evidence has been accumulating 
on the effectiveness of the endoscopic management in 
BE treatment. There is generally high level of agreement 
across various guidelines regarding the management of 
non­dysplastic BE and BE with HGD or EAC. However, 
the therapy administered to patients with LGD is often 
a controversial topic. The changing guidelines for the BE 
endoscopic management are shown in Table 2.
Management of non-dysplastic and LGD BE
In 2011, AGA proposed using radiofrequency ablation 
(RFA; with or without endoscopic mucosal resection, 
EMR) for selected non­dysplastic BE individuals at risk 
for progression; however, the risk criteria were not fully 
defined. Then, it was also stated that RFA in LGD leads 
to reversion to normal­appearing squamous epithe­
lium in > 90% of cases, and ablation should be the 
showing a significantly lower rate of progression to LGD, 
HGD, or EAC in patients who had a history of antireflux 
surgery or PPI use[109]. Moreover, a recent meta­analysis 
of observational studies showed that PPI therapy was 
associated with a 71% risk reduction in BE progression 
with a trend towards a dose­response relationship, 
considering PPI use for > 2­3 years, protective against 
EAC or HGD[110]. However, a considerable heterogeneity 
was observed, and chemopreventive high­quality 
prospective trials of PPIs in patients with BE are 
warranted[110,111]. 
Complete, but not partial, acid suppression by 
PPIs over 6 mo, as measured by 24­h pH monitoring, 
decreases markers of epithelial proliferation and 
increases cell differentiation markers in patients with 
BE[112]. Similarly, a randomized clinical trial showed that 
a high­dose esomeprazole promoted a decrease in 
proliferative markers, concomitantly with a decrease in 
apoptotic cell death[113]. Overall, PPI therapy seems to 
be important not only because it reduces the acidity, 
and therefore the chemical damage, of the refluxate but 
also because PPIs have anti­inflammatory properties 
independent of their acid­suppressive effects[114]. 
A large case­control study by Nguyen et al[115] indi­
cated that using PPI, nonsteroidal anti­inflammatory 
drugs (NSAID)/aspirin, or statin therapy in patients 
with BE might reduce the risk of developing EAC. 
Furthermore, an interesting study found that the 
incubation of isolated cells from mucosal biopsies of 
BE metaplasia with aspirin and omeprazole together 
induced a significantly greater reduction in proliferative 
activity than that induced separately by any of the two 
drugs, thus suggesting a synergistic effect of the two 
  Guidelines NDBE IND LGD HDG
  BOB CAT[90] Not 
recommended1
≤ 12 mo 6-12 mo Not 
recommended
  ACPG[57] < 3 cm 3-5 yr ≤ 6 mo 6 mo Not 
recommended≥ 3 cm 2-3 yr
  BSG[58] < 3 cm 3-5 yr ≤ 6 mo 6 mo Not 
recommended≥ 3 cm 2-3 yr
  ASGE[100] 3-5 yr No specific 
time frame
12 mo2 3 mo3
  ACP[101] 3-5 yr Not 
recommended
No specific 
time frame
No specific 
time frame
  AGA[59] 3-5 yr Not
recommended
6-12 mo 3 mo3
Table 1  Comparison of endoscopic surveillance recommendations 
for Barrett’s esophagus in currently available guidelines
1If undertaken, surveillance should be directed at high-risk groups (i.e., 
composite risk factors including but not limited to 50 years of age or older, 
white race, male sex, central obesity, the length of the segment, and the 
symptom duration, frequency and severity), unless the life expectancy ≤ 5 yr; 
2Six months to confirm LGD; 3In the absence of eradication therapy. BOB 
CAT: Benign Barrett’s and Cancer Taskforce; ACPG: Australian Clinical 
Practice Guidelines; BSG: British Society for Gastroenterology; ASGE: 
American Society for Gastrointestinal Endoscopy; ACP: American College 
of Physicians; AGA: American Gastroenterological Association; NDBE: 
Non-dysplastic Barrett’s esophagus; IND: Indefinite for dysplasia; LGD: 
Low-grade dysplasia; HGD: High-grade dysplasia.
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or with LGD detected on a single endoscopy[90]. The 
former group should be treated with ablative therapy 
rather than only followed up with[90]. 
Management of HGD and early-stage EAC
In HGD, there is a high rate of progression to EAC 
(6%­19% per year), and endoscopic therapy is a 
well­established therapy for these cases. All asso­
ciations recommend endoscopic therapy (with a 
combination of EMR followed by the ablation of residual 
BE mucosa) for HGD and intramucosal EAC (Table 
2)[58,59,118­120]. Previously, the standard of treatment was 
esophagectomy due to high cure rates, but it was also 
characterized by substantial mortality (2%­5%) and 
morbidity (30%­50%)[121].
In 2013, the European Society for Medical Oncology 
stated that surgery is the treatment of choice in early 
EAC (Tis­T1a, N0). However, endoscopic resection is 
an alternative treatment option for selected patients 
because similar cure rates in specialized centres have 
been reported[122]. Similarly to BE with dysplasia, 
endoscopic therapy for early­stage EAC includes 
resection and ablation techniques[123]. EMR successfully 
eradicates 91% to 98% of T1a EAC[123,124], with a 
therapeutic option in those cases[59]. In the American 
Society for Gastrointestinal Endoscopy guidelines, 
endoscopic ablation therapy was suggested as the 
management option in selected patients with non­
dysplastic BE. They also allowed the consideration of 
endoscopic resection or ablation in all LGD cases[100]. 
However, according to the British guidelines, the 
endoscopic treatment was not routinely recommended 
in non­dysplastic BE or in LGD[58]. 
Recent management strategies, established by the 
international BOB CAT consensus, include the following: 
(1) endoscopic resection/ablation is not recommended 
in benign BE; and (2) patients with LGD on a single 
occasion, without higher­risk features, should be 
managed with endoscopic surveillance continued for 
6­12 mo (provided the patient is fit for endoscopy and 
is not already undergoing therapy)[90]. The absence 
of dysplasia in two subsequent upper endoscopies 
identifies a cohort of patients, previously diagnosed with 
LGD, who are at low risk of neoplastic progression and 
can keep on routine surveillance. Moreover, the BOB 
CAT consensus states that BE patients with multifocal 
LGD and/or with LGD that persists have an increased 
risk for neoplastic progression than those with focal LGD 
  Guidelines NDBE LGD HGD/intramucosal EAC
  ACG[118] Not recommended Not recommended Endoscopic ablation or surgical esophagectomy
  AGA[59] RFA (± EMR) for select 
individuals at risk for 
progression
RFA is a therapeutic 
option
Endoscopic therapy with RFA, PDT or EMR
EMR in BE dysplasia with a visible mucosal irregularity
Before proceeding with esophagectomy, patients with HGD or intramucosal EAC 
should be referred for evaluation by surgical specialized centres
  BAD CAT[120] - - Endoscopic treatment should be preferred over endoscopic surveillance or 
surgery for the management of most patients with HGD/intramucosal EAC
RFA is currently the best available ablation technique for the treatment of flat 
HGD and for the eradication of residual BE after focal EMR
In the HGD endoscopic resection of all visible abnormalities, cap and snare and 
band ligation with resection are equally effective
  ASGE 
  (2012)[100]
Consider endoscopic ablation in 
select cases
Consider endoscopic 
resection or ablation
Consider endoscopic resection or RFA ablation. Consider EUS for local staging 
and lymphadenopathy
Consider surgical consultation
  BSG[58] Not recommended Not routinely 
recommended
Endoscopic therapy preferred over esophagectomy
  ASGE 
  (2013)[123]
- - EMR is indicated for nodular BE and T1a EAC and may be used for flat BE with 
HGD
ESD can be used in similar situations but is preferred to EMR for large areas of 
dysplasia or T1b EAC (i.e., confined to the submucosa)
Ablation techniques may be used alone or in combination with mucosal resection 
techniques
  BOB CAT[90] If the lesion is visible, endoscopic resection for diagnosis 
is then appropriate ablative therapy
-
Not recommended Lower risk: Intense 
surveillance.
Higher risk:
Ablative therapy with 
follow-up
 Table 2  Recommendations for endoscopic eradication therapy in Barrett’s esophagus
ACG: American College of Gastroenterology; AGA: American Gastroenterology Association; BAD CAT: Barrett’s Dysplasia and Cancer Taskforce; ASGE: 
American Society for Gastrointestinal Endoscopy; BSG: British Society for Gastroenterology; BOB CAT: Benign Barrett’s and Cancer Taskforce; RFA: 
Radiofrequency ablation; EMR: Endoscopic mucosal resection; PDT: Photodynamic therapy; EUS: Endoscopic ultrasound; ESD: Endoscopic submucosal 
dissection; BE: Barrett’s esophagus; NDBE: Non-dysplastic Barrett’s esophagus; LGD: Low-grade dysplasia; HGD: High-grade dysplasia; EAC: Esophageal 
adenocarcinoma.
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determination of margins of resection[119,128­130], which 
have crucial implications in the appropriate choice 
of treatment and outcomes[131]. However, ablation 
therapies can be applied to larger surface areas and to 
different resection locations[132]. 
The AGA guidelines recommended RFA, PDT, 
cryotherapy, thermal energy application, and EMR in BE 
eradication in 2011[59,133]. Currently, the most commonly 
used technologies are RFA and EMR used alone or in 
combination. In most cases, ablation techniques are 
used in combination with resection techniques (multi­
modal therapy), wherein ablation techniques are applied 
following EMR or ESD that are used to remove macro­
scopically visible lesions[119]. 
Endoscopic mucosal resection
EMR is an endoscopic technique useful in the resection 
of macroscopically visible BE lesions that are less than 
2 cm in diameter. To lift the lesion from the muscularis 
propria, normal saline or dilute epinephrine is first 
injected into submucosa[119]. EMR can be performed with 
either EMR­cap or EMR­ligation techniques. The former 
uses suction to retract the target tissue into a plastic 
cap that is attached to the endoscope, and a snare is 
closed around the lesion, followed by electrocautery. 
The latter uses suction to aspirate the tissue, followed 
by band deployment, to create a pseudopolyp. Then, a 
cancer­free survival similar to and a lower morbidity 
than surgical resection[125]. The long­term survival of 
742 patients with TisN0M0 and T1N0M0 EAC treated 
with either endoscopic modalities (most commonly 
EMR) and surgical resection was similar[126]. Zehetner et 
al[127] demonstrated similar survival in patients with HGD 
and intramucosal EAC treated with endoscopic resection 
and ablation than surgical resection, with a significantly 
lower morbidity associated with endoscopic treatment.
Categories of endoscopic BE eradication modalities 
Multiple modalities may be employed for the endoscopic 
eradication of BE. There are two main types of endos­
copic therapy: Tissue­acquiring techniques, which 
include EMR and endoscopic submucosal dissection 
(ESD), and ablative techniques, which include thermal 
techniques (RFA, multipolar electrocoagulation, argon 
plasma coagulation), cryotherapy and photochemical 
techniques (photodynamic therapy, PDT)[119]. Examples 
of ablative therapies are shown in Table 3. 
The great advantage of both EMR and ESD, com­
pared to ablative therapies, is that specimens for histo­
pathological analysis at the time of treatment can be 
obtained. The diagnosis of dysplasia and neoplasia in 
EMR specimens is improved, particularly because of the 
upstaging of cases previously diagnosed as dysplasia 
and the assessment of the depth of invasion with the 
  Ablation 
  modalities
Description of the technique Outcome Ref.
  RFA RFA uses a balloon-based circumferential array of closely 
spaced electrodes to deliver radiofrequency energy to the 
esophageal mucosa. With this technique, the mucosa is ablated 
to the submucosal level. A smaller, endoscope-mounted, 
radiofrequency catheter ablation device could be used for the 
focal ablation of metaplasia that could remain after treatment 
with the circumferential system. A follow-up endoscopy is at 3 
mo when any remaining metaplasia is ablated, with a further 
follow-up endoscopy at 1 yr
A landmark large, multicentre, randomized trial showed that 
RFA can eliminate HGD, reducing the risk of EAC compared 
with a sham procedure. Overall, the eradication rates for 
HGD range from 79% to 90% and from 69% and 97% for 
NDBE/LGD patients
RFA is safer and easier to administer, and it causes fewer 
major complications, particularly stricture formation, than 
PDT
[133,145]
  APC APC produces a flow of ionized argon plasma that generates a 
high-frequency monopolar current to the BE surface under direct 
vision
Different eradication rates for NDBE and LGD in the short 
term ranged from 36% to 100% for NDBE and rates of 
recurrence between 62% and 100% for LGD patients
[133]
  PDT PDT is based on the injection of a light sensitizing drug (e.g., 
porfimer sodium) into the patient and then the exposure of a 
portion of the esophagus to light of a specific wavelength, which 
would lead to dysplasia cell death. Once the photosensitizer is 
activated by the light, it generates oxygen free radicals that result 
in cytotoxicity to the mucosal cells
The eradication rates for HGD range from 77% to 100%, and 
those for NDBE/LGD range from 50%-100% of patients 
The limitations include the cost of the intravenous agent, 
the prolonged period (weeks) of photosensitivity following 
exposure, and an appreciable post-treatment stricture rate
[133]
  CRY CRY is a non-contact method of cryotherapy that involves an 
endoscopically directed spray of liquid nitrogen at -196 ℃ 
directly onto the Barrett’s mucosa
The advantage is a lack of contact with mucosa and hence can be 
applied to irregularity, which would
make the application of contact therapies such as RFA 
challenging
The rates of complete eradication are approximately 68%-97% 
for HGD and 57% for NDBE
The current literature is inadequate to assess the ability of 
CRY to achieve sustained reversion of the metaplastic mucosa 
to normal-appearing squamous epithelium in subjects at any 
stage of BE. Further longitudinal studies are needed
[133,156]
  MPEC MPEC uses an endoscopic multipolar electrical probe, which 
is used to control gastrointestinal haemorrhage that applies 
electrical energy at 50 W so that all BE surfaces are treated
Complete eradication in 65%-100% of NDBE. 
This technique is very much operator dependent and causes 
dysphagia as the most common side effect
[133]
Table 3  Ablation therapy in Barrett’s esophagus
RFA: Radiofrequency ablation; APC: Argon plasma coagulation; PDT: Photodynamic therapy; CRY: Cryoablation; MPEC: Multipolar electrocoagulation; 
EAC: Esophageal adenocarcinoma; BE: Barrett’s esophagus; IM: Intestinal metaplasia; NDBE: Non-dysplastic Barrett’s esophagus; LGD: Low-grade 
dysplasia; HGD: High-grade dysplasia. 
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is technically more difficult, particularly due to narrow 
lumen, fibrosis caused by chronic reflux, and the thin 
wall of the esophagus. Furthermore, esophageal ESD 
showed frequent complications, such as bleeding, 
perforation (rates between 2% and 5%), and stricture 
formation (rates between 5% and 17.2%)[119,140­143]. 
Prophylactic steroid injection following esophageal 
ESD has been shown to decrease the risk of stricture 
formation[144]. 
Radiofrequency ablation
Radiofrequency ablation (RFA) delivers high­frequency 
energy to the esophageal mucosa to achieve tissue 
necrosis. The depth of ablation is between 500 and 
1000 μm. There are two systems available: A 3­cm­
long balloon ablation catheter (HALO 360) intended to 
treat circumferential LSBE (Figure 1) and an endoscope­
mounted targeted device (HALO 90, HALO 60, HALO 
ULTRA) to treat SSBE and BE islands and tongues 
(Figure 1)[132]. The technique involves mucosal ablation 
under endoscopic guidance followed by the removal of 
the adhered white coagulum in the ablated area and 
then by repeat treatment of the same area, all within 
one endoscopic session (Figure 2). Multiple endoscopic 
treatments may be required depending on the length of 
the BE segment and the tissue response. Treatment is 
usually performed every 2­3 mo[132]. 
Among patients undergoing RFA, a complete 
eradication of dysplasia occurred in 90.5% and in 81% 
hexagonal snare and electrocautery are used to resect 
the lesion[119]. These two techniques have shown similar 
diagnostic accuracy and safety[119,134]. However, with 
the ability to perform several resections with a single 
intubation and kit, EMR­ligation technique seems to be 
faster and less expensive[134]. 
Complete remission of dysplasia and intestinal 
metaplasia is achieved in > 80%­90% of patients 
undergoing EMR with or without concurrent ablative 
therapy[135,136]. Recently, a large group of patients 
with BE and T1a EAC treated with endoscopic therapy 
reported a 96.3% complete response rate. The overall 
survival rate was 91% at 5 years and 75% at 10 
years[137]. 
Potential complications of EMR are bleeding, per­
foration, and stricture formation. Delayed bleeding 
is infrequent, but immediate post­resection bleeding 
can occur in 10% of patients[138]. Perforation rates are 
reported to be less than 3%. The extent of mucosa 
removed by EMR is the risk factor for stricture formations 
(37% of cases), the majority of which are successfully 
managed by endoscopic dilation[124,135,139]. 
ESD
ESD is more likely to achieve an en bloc resection, 
usually of lesions > 2 cm. First, a lesion is lifted off 
the muscularis propria with an injected solution; then, 
dissection in the submucosal plane, using a variety of 
dissection knives, is performed. ESD in the esophagus 
A
B
Figure 1  Radiofrequency ablation to treat Barrett’s esophagus. A: HALO 90 to treat short segments, islands and tongues of Barrett’s esophagus; B: Balloon 
ablation catheter (HALO 360) intended to treat long-segment circumferential Barrett’s esophagus. Material from Department of Digestive Tract Disease, Medical 
University of Lodz, Poland.
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adequately select patients before surgery[157­159]. 
Laparoscopic partial and total fundoplications 
are currently the best available surgical techniques 
to treat severe GERD[158]. The two major competing 
procedures are the laparoscopic Nissen fundoplication 
and the posterior partial Toupet hemifundoplication. 
Randomized studies have shown a similar outcome at 
5 years but a higher rate of side effects (dysphagia, 
bloating, and flatulence) and a higher reoperation rate 
in the Nissen group than in the Toupet group[160,161]. 
In contrast, other studies have reported minor side 
effects and a lower reoperation rate for the Nissen 
procedure[162­164]. Because of these controversies, the 
choice of fundoplication technique should be left to the 
individual preferences of the surgeon. 
Recently, the LOTUS trial showed a comparable rate 
of symptom control between surgery and escalating 
doses of PPIs[165]. Surgery should be considered for 
younger patients, particularly in cases with a high risk 
of progression with large hiatal hernias, severe reflux 
symptoms, and a long history of disease to prevent 
the progression to BE[166,167]. However, there is limited 
evidence of the effectiveness of antireflux surgery in 
reducing the extent of BE and the risk of progression 
to cancer, as well as the regression of BE. Thus, after 
antireflux surgery, endoscopic surveillance has to be 
maintained[168­171]. Of note, it has been shown that 
neoplastic progression after antireflux surgery is due 
primarily to the subsequent recurrence of reflux[172]. 
Surgery is still the treatment of choice in early 
EAC; however, in 2011, AGA stated that most patients 
with HGD BE (70%­80%) can be successfully treated 
with endoscopic eradication therapy. Esophagectomy 
in patients with HGD is an alternative; however, the 
current data suggest a lower morbidity with ablative 
therapy[59]. The important issue is the choice of surgical 
centres specializing in the treatment of foregut cancers 
and HGD. In 2012, the Barrett’s Dysplasia and Cancer 
Task Force (BAD CAT) consensus group stated that 
endoscopic treatment is preferred to surgery in most 
cases of HGD; however, esophagectomy results in a 
long­term cure. Moreover, there is no strong evidence 
that fundoplication reverses HGD[120]. 
of LGD and HGD patients, respectively, at a 12­mo 
follow­up. Overall, 77.4% of patients in the ablation 
group had complete eradication of intestinal meta­
plasia[145]. Subsequently, RFA therapy provided an 
acceptable safety profile associated with a low rate of 
disease progression for up to 3 years[146]. RFA efficacy 
has been demonstrated in several other studies, with 
eradication rates of metaplasia and dysplasia ranging 
from approximately 81%­92.6% and 75%­88.2%, 
respectively[119,147,148]. Moreover, reductions in rates of 
progression from LGD and HGD to cancer have been 
demonstrated in randomized controlled trials with 
RFA[145,147]. 
RFA is safe and well tolerated. The most common 
complications reported include chest pain lasting less 
than one week, strictures requiring dilation (6%­8%), 
gastrointestinal haemorrhage (1%), and perforation 
(less than 1%)[132,145,149]. 
Incomplete response to ablation is possible, parti­
cularly in cases of a longer duration of dysplasia, longer 
BE segments, a loss of p16 locus or polysomy (detected 
by FISH) and poor reflux control[119,150­152]. The presence 
or persistence of intestinal metaplasia under new 
squamous epithelium is known as “buried metaplasia”. 
Because of its malignant potential, it is important 
to remember that it could be invisible in endoscopic 
surveillance and in superficial biopsies. The prevalence 
of buried metaplasia was 14% after PDT and 0.9% after 
RFA, but the results could be underestimated[119,153,154]. 
Similar rates of recurrence have been reported with 
all modalities of BE endotherapy (RFA, PDT and 
cryotherapy). Most recurrences can be treated endoscopi­
cally if detected early. Thus, post­treatment endoscopic 
surveillance is needed[119,155,156]. 
SURGICAL THERAPY
Surgical treatment is indicated particularly in patients 
who need long­term treatment of GERD (i.e., pati­
ents with persistent troublesome symptoms and/
or a progression of disease despite adequate PPI 
therapy)[157,158]. To achieve an increase in the quality of 
life, proper diagnostic testing should be performed to 
Figure 2  Improvement after radiofrequency ablation of Barrett’s esophagus. Material from Department of Digestive Tract Disease, Medical University of Lodz, 
Poland.
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degeneration would lead to more cost­effective strategies 
for the prevention of EAC, helping select those patients 
deserving a close endoscopic follow­up. At present, the 
management of patients with LGD represents a main 
issue due to its unpredictable natural history, the lack of 
cost­effectiveness data regarding the surveillance of LGD 
and high disagreement between pathologists in LGD 
diagnosis[100]. 
The area of BE therapeutic management is rapidly 
evolving. Unequivocal data on the use of drugs such 
as PPIs, aspirin or statins in the chemoprevention 
of BE are lacking. At the moment, there is no doubt 
regarding the use of PPIs for symptom control[58,59]. 
Endoscopic eradication therapies have been shown to 
be effective in patients with BE/EAC, and new therapies 
have appeared. BE containing HGD and/or early­stage 
EAC can be treated endoscopically instead of with 
surgical esophagectomy. Moreover, recent management 
strategies, including a de­escalation strategy for lower­
risk patients and escalation to intervention with follow­
up for higher­risk patients, have been established[90,120]. 
The main objective of endoscopic therapy should be 
the elimination of all intestinal metaplasia because 
the recurrence of neoplasia appears to be higher in 
individuals who do not achieve a full eradication of 
BE[124]. 
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